NCT01746238View on ClinicalTrials.gov

Bevacizumab/Doxorubicin/Radiation for Sarcoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

December 31, 2025

Conditions
Sarcoma
Interventions
DRUG

Bevacizumab

Intravenous infusion, every 2 weeks, 3 doses total

DRUG

Doxorubicin

Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks

RADIATION

Radiation Therapy

Daily, Monday-Friday, for 6 weeks

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01746238 - Bevacizumab/Doxorubicin/Radiation for Sarcoma | Biotech Hunter | Biotech Hunter